For example, PSMA‐targeted systems such as BIND‐014 achieved strong tumor regression in xenografts yet delivered only modest outcomes in phase II trials, largely due to heterogeneous PSMA expression across patients [217]. The gene discussed is FOLH1; the disease is neoplasm.